Tech Company Financing Transactions

Melinta Therapeutics Funding Round

Melinta Therapeutics closed a $70 million Series C venture capital round on 2/10/2014. Backers included Vatera Healthcare Partners and private investors.

Transaction Overview

Announced On
2/10/2014
Transaction Type
Venture Equity
Amount
$70,000,000
Round
Series C
Investors

Vatera Healthcare Partners (Lead Investor) (Thomas Koestler)

Proceeds Purpose
Proceeds from this financing will be used, in part, to advance delafloxacin, a differentiated fluoroquinolone, through an ongoing Phase 3 study of a single oral dose in individuals with uncomplicated gonorrhea, to the submission of a New Drug Application (NDA) in late 2014. In addition, the funds will support delafloxacin's two ongoing Phase 3 trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and the selection of lead candidates from Melinta's RX-04 research program.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 George St. 301
New Haven, CT 06511
USA
Email Address
Overview
Melinta Therapeutics' mission is to discover, develop and commercialize groundbreaking antibiotics to overcome drug-resistant, life-threatening infections.
Profile
Melinta Therapeutics LinkedIn Company Profile
Social Media
Melinta Therapeutics Company Twitter Account
Company News
Melinta Therapeutics News
Facebook
Melinta Therapeutics on Facebook
YouTube
Melinta Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Christine Miller
  Christine Miller LinkedIn Profile  Christine Miller Twitter Account  Christine Miller News  Christine Miller on Facebook
Chief Financial Officer
Peter Milligan
  Peter Milligan LinkedIn Profile  Peter Milligan Twitter Account  Peter Milligan News  Peter Milligan on Facebook
VP - Bus. Development
Michael McGuire
  Michael McGuire LinkedIn Profile  Michael McGuire Twitter Account  Michael McGuire News  Michael McGuire on Facebook
VP - Finance
Susan Blum
  Susan Blum LinkedIn Profile  Susan Blum Twitter Account  Susan Blum News  Susan Blum on Facebook
VP - General Counsel
Jennifer Sanfilippo
  Jennifer Sanfilippo LinkedIn Profile  Jennifer Sanfilippo Twitter Account  Jennifer Sanfilippo News  Jennifer Sanfilippo on Facebook


 

 

Browse more venture capital transactions:

Prev: 2/10/2014: HiConversion venture capital transaction
Next: 2/10/2014: CloudOne venture capital transaction

 

Share this article

 


About Database of VC Transactions

We do our best to document every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary